Ms. Ingrid Zerbe reports

INTELGENX ANNOUNCES VOTING RESULTS ON ELECTION OF DIRECTORS

At IntelGenx Technologies Corp.'s annual meeting of shareholders held on May 9, 2023, shareholders voted in favour of all items of business put forth by the company, including the election of the directors, by a majority of the votes cast by shareholders present or represented by proxy.

The annual meeting was held in a virtual-only format, for those who were shareholders of the company at the close of business on March 13, 2023, pursuant to notice and proxy materials duly communicated to them. As of the record date, there were 174,646,197 shares outstanding of the company's common stock at 0.001 cent par value. Shareholders as of the record date holding 106,501,774 shares (60.98 per cent) of the IntelGenx common stock were present at the annual meeting or per proxy. Each such shareholder was entitled to one vote for each share of the IntelGenx common stock held on the record date.

At the annual meeting, the following matters were submitted to votes of the company's shareholders:

1. The election of eight directors;
2. The ratification of Richter LLP as the company's independent auditor for the fiscal year ending Dec. 31, 2023;
3. The advisory vote on executive compensation.

Detailed voting results on the election of directors are as noted herein.

About IntelGenx Technologies Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next-generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

We seek Safe Harbor.